CSIMarket
 


Orgenesis Inc   (ORGS)
Other Ticker:  
 

Cumulative Orgenesis Inc 's Working Capital Ratio for Trailing Twelve Months Period

ORGS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ORGS Working Capital Ratio for Trailing Twelve Months Period

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Growth -21.75 % -8.62 % 3.55 % 151.86 % -10.53 %
Y / Y Current Assets Growth -63.49 % 105.96 % 79.82 % -12.34 % -46.79 %
Working Capital Ratio for Trailing Twelve Months Period 1.78 1.91 1.56 1.32 1.85
Total Ranking # 2102 # 2136 # 2923 # 3223 # 2863
Seq. Current Liabilities Growth -8.8 % -12.39 % -53.44 % 110.33 % 6.5 %
Seq. Current Assets Growth -81.2 % 6.76 % 45.4 % 25.13 % 6.03 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2023
On the trailing twelve months basis Despite year on year decrease in Orgenesis Inc 's average Current Liabilities to $13 millions, Working Capital Ratio for Trailing Twelve Months Period to 1.78 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 475 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Orgenesis Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ORGS
Working Capital Ratio ORGS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 476
Sector # 970
S&P 500 # 3467


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
4.88 1.8 0.35
(Sep 30 2020)   (Aug 31 2017)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Ampio Pharmaceuticals inc   4.90 
Dynavax Technologies Corporation  4.85 
Enveric Biosciences Inc   4.76 
Galmed Pharmaceuticals Ltd   4.76 
Scynexis Inc   4.76 
Imunon Inc   4.74 
Y mabs Therapeutics inc   4.72 
Purple Biotech Ltd   4.71 
Onconova Therapeutics inc   4.70 
Pharming Group N v   4.65 
Trevena inc   4.64 
Decibel Therapeutics Inc   4.62 
Karyopharm Therapeutics Inc   4.61 
Corvus Pharmaceuticals Inc   4.56 
Arvinas Inc   4.56 
Chemocentryx Inc.  4.54 
Revance Therapeutics Inc   4.53 
2seventy Bio Inc   4.51 
Mirum Pharmaceuticals Inc   4.51 
Adc Therapeutics Sa  4.51 
Harmony Biosciences Holdings inc   4.49 
Macrogenics Inc   4.48 
Nurix Therapeutics Inc   4.47 
Neubase Therapeutics inc   4.47 
Bullfrog Ai Holdings Inc   4.46 
Praxis Precision Medicines Inc   4.44 
Arrowhead Pharmaceuticals Inc   4.44 
G1 Therapeutics Inc   4.43 
Qilian International Holding Group Limited  4.40 
Neurobo Pharmaceuticals Inc   4.39 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com